HB Wealth Management LLC Sells 71 Shares of Medpace Holdings, Inc. $MEDP

HB Wealth Management LLC trimmed its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 768 shares of the company’s stock after selling 71 shares during the period. HB Wealth Management LLC’s holdings in Medpace were worth $241,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in MEDP. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Brooklyn Investment Group increased its position in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after buying an additional 71 shares during the period. Whittier Trust Co. increased its position in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after buying an additional 35 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in Medpace in the 1st quarter worth approximately $60,000. Finally, Assetmark Inc. increased its position in Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after buying an additional 43 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Stock Performance

Medpace stock opened at $531.85 on Wednesday. The firm has a market cap of $14.94 billion, a P/E ratio of 39.54, a P/E/G ratio of 3.34 and a beta of 1.40. The business’s fifty day moving average is $478.06 and its two-hundred day moving average is $370.91. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $547.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business’s revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 41,801 shares of the business’s stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $453.11, for a total value of $18,940,451.11. Following the transaction, the president owned 36,503 shares of the company’s stock, valued at approximately $16,539,874.33. The trade was a 53.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the company’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares in the company, valued at $4,654,350. This trade represents a 22.48% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,266 shares of company stock valued at $74,111,427. Insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on MEDP. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Cowen lowered Medpace from a “buy” rating to a “sell” rating in a report on Wednesday, July 23rd. Weiss Ratings reissued a “buy (b-)” rating on shares of Medpace in a report on Saturday, September 27th. Jefferies Financial Group lifted their price objective on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a report on Tuesday, September 9th. Finally, Truist Financial lifted their price objective on Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Three analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $422.27.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.